Rapport Therapeutics Inc
NASDAQ:RAPP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Rapport Therapeutics Inc
NASDAQ:RAPP
|
US |
|
C
|
CG Oncology Inc
NASDAQ:CGON
|
US |
|
Etteplan Oyj
F:EPL
|
FI |
|
B
|
Bien Sparebank ASA
OSE:BIEN
|
NO |
|
Grown Rogue International Inc
OTC:GRUSF
|
US |
|
C
|
CSA Cosmic Co Ltd
KOSDAQ:083660
|
KR |
|
E
|
EMC PCL
SET:EMC
|
TH |
|
S
|
Space Hellas SA
ATHEX:SPACE
|
GR |
|
O
|
Omer SpA
MIL:OMER
|
IT |
|
O
|
Omni Inovasi Indonesia Tbk PT
IDX:TELE
|
ID |
|
F
|
Forth Smart Service PCL
SET:FSMART
|
TH |
|
T
|
T Man Pharmaceutical PCL
SET:TMAN
|
TH |
|
G
|
George Weston Ltd
OTC:WNGRF
|
CA |
|
Banca Profilo SpA
MIL:PRO
|
IT |
|
Societe BIC SA
PAR:BB
|
FR |
Intrinsic Value
Is RAPP undervalued or overvalued?
See the intrinsic value estimate for Rapport Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
RAPP looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with RAPP’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Rapport Therapeutics Does
Rapport Therapeutics is a biopharmaceutical company that develops medicines for brain and nervous system disorders. Its work centers on finding the specific molecular targets that drive these diseases and designing drug candidates that can act on those targets more precisely than older treatments. The company does not sell a broad consumer product line; it is focused on building a pipeline of prescription drug candidates for clinical testing and, if successful, future approval.
- Headquarters
- United States of America US
- Employees
- 84
- IPO date
- Jun 7, 2024
Earnings Waterfall
Rapport Therapeutics Inc
The intrinsic value for Rapport Therapeutics Inc (RAPP) under the Base Case is hidden USD.
Compared with the current market price of 27.695 USD, the stock appears hidden.